Sunshine Biopharma (Sunshine Biopharma) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Sunshine Biopharma Debt-to-Equity?

Sunshine Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.12 Mil. Sunshine Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.54 Mil. Sunshine Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $21.21 Mil. Sunshine Biopharma's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sunshine Biopharma's Debt-to-Equity or its related term are showing as below:

SBFMW' s Debt-to-Equity Range Over the Past 10 Years
Min: -17.02 Med: -1.18 Max: 8.96
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Sunshine Biopharma was 8.96. The lowest was -17.02. And the median was -1.18.

SBFMW's Debt-to-Equity is ranked better than
89.31% of 851 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs SBFMW: 0.03

Sunshine Biopharma Debt-to-Equity Historical Data

The historical data trend for Sunshine Biopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Debt-to-Equity Chart

Sunshine Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.97

-2.00

8.96

0.04

0.03

Sunshine Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.04	0.03	0.03	0.03

Competitive Comparison of Sunshine Biopharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunshine Biopharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Debt-to-Equity falls into.

Sunshine Biopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sunshine Biopharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.119	+	0.539)	/	21.207
	=	0.03

Sunshine Biopharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.119	+	0.539)	/	21.207
	=	0.03

Sunshine Biopharma (NAS:SBFMW) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sunshine Biopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Biopharma (Sunshine Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFMW) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SBFM:USA

Address

6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5

Website

https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).